


PHARMACEUTICAL 2020



BIOSPECIFICS TECHNOLOGIES CORP Rank 5 of 362





PHARMACEUTICAL 2020



BIOSPECIFICS TECHNOLOGIES CORP Rank 5 of 362

The relative strengths and weaknesses of BIOSPECIFICS TECHNOLOGIES CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of BIOSPECIFICS TECHNOLOGIES CORP compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 377% points. The greatest weakness of BIOSPECIFICS TECHNOLOGIES CORP is the variable Assets, Current, reducing the Economic Capital Ratio by 115% points.

The company's Economic Capital Ratio, given in the ranking table, is 370%, being 673% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	109,271
Cost of Goods Sold	0
Intangible Assets	573
Liabilities, Current	1,422
Liabilities, Non-Current	0
Other Assets	16,809
Other Compr. Net Income	0
Other Expenses	5,829
Other Liabilities	0
Other Net Income	1,987
Property and Equipment	0
Research and Development	590
Revenues	38,188
Selling, General and Administrative Expense	9,285

Output Variable	Value in 1000 USD
Assets	126,653
Liabilities	1,422
Expenses	15,705
Stockholders Equity	125,231
Net Income	24,470
Comprehensive Net Income	24,470
Economic Capital Ratio	370%